The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: A review of phase III trials

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 14-27

  Funaioli, C ^a   Longobardi, C ^a   Martoni, Andrea Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Advanced colorectal cancer; Chemotherapy; Overall survival; Quality of life; Toxicity

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; OXALIPLATIN; PLACEBO; RALTITREXED; TRIMETREXATE; URACIL; YTTRIUM;

ALOPECIA; ANEMIA; ANOREXIA; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG RESPONSE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; LETHARGY; LEUKOPENIA; META ANALYSIS; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 41149091810     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.14     Document Type: Review

References (34)

1. Advanced colorectal cancer meta-analysis project: Modulation of 5-fluoruracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rates. J Clin Oncol 1992; 10:896-903.
2. The Meta-analysis Group in Cancer: Modulation of Fluoruracil by leucovorin in patients with advanced colorectal cancer: an updated Meta-analysis. J Clin Oncol 2004: 22: 3766-3775.
3. Meyerhardt JA and Mayer RJ: Drug therapy: systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476-87.
4. Best L, Simmonds P, Baughan C, et al. Palliative chemotherapy for advanced or metastatic colorectal cancer (Review). The Cochrane database of Systematic Reviews 2000; Issue 1. Art No. CD001545. DOI: 10.1002/14651858. CD001545
5. de Kort SJ, Willemse PHB, Habraken JM, de Haes HC, Willems DL, Richel DJ: Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: A review of randomized controlled clinical trials. Eur J Cancer 2006; 42(7):835-45.
6. De Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-815.
7. Kalofonos HP, Nicolaides C, Samantas E, et al: A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. Am J Clin Oncol 2002; 25:23-30.
8. Kohne CH, Wils J, Lorenz M, et al: Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003;21:3721-3728.
9. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
10. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-4106.
11. Carmichael J, Popiela T, Radstone D, et al: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617-3627.
12. Douillard JY, Hoff PM, Skillings JR, et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-3616.
13. Maughan TS, James RD, Kerr DJ, et al: Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002, 359, 1555-63
14. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
15. Kohne CH, Van Cutsem E, Wils J, et al: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23 (22), 4856-65.
16. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
17. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
18. Blanke CD, Shultz J, Cox J, et al: A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol 2002;13: 87-91.
19. Punt CJ, Keizer HJ, Douma J, et al: Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol 2002; 13:81-86.
20. Sobrero A, Zaniboni A, Frassineti GL, et al: Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers. Ann Oncol 2000;11:1413-1420.
21. Price TJ, Ross PJ, Hickish T, et al: Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer 2004;3: 235-242.
22. Toumigand C, Andre T, Achille E, et al: FOLHRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237
23. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23(22):4866-75.
24. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
25. Goldberg RM, Sargent DJ, Morton RF, et al: Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006; 24: 3347-3353.
26. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
27. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352 (9138): 1413-8.
28. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352 (9138): 1407-12.
29. Lal R, Dickson J, Cunningham D, et al: A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol 2004; 22: 3023-3031.
30. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21: 807-814.
31. Gray B, Van Hazel G, Hope M, et al: Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12: 1711-1720.
32. Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003 21:2059-2069.
33. Grothey A and Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005; 23(36):9441-2.
34. Benson AB and Goldberg RM. Optimal use of the combination of irinotecan and 5-Fluoruracil Semin Oncol 2003: 30 (3); 68-77.